Geisel School of Medicine Board of Overseers
Steven Gillis, PhD (DC '78)
Steven Gillis is a Managing Director with ARCH, joining the firm as a Venture Partner in 2005. He is focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. Dr. Gillis was the founder and director of both Corixa Corp. and Immunex Corp. For Corixa Corp. Dr. Gillis served as the company's CEO from its inception and its Chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to his work with Corixa, Dr. Gillis was the founder and director of Immunex Corp. where he also acted as its Director of Research and Development, Chief Scientific Officer, CEO of Immunex's R&D subsidiary and interim CEO.
Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. A pioneer in the field of cytokines and cytokine receptors, he has directed the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluable TNF receptor-Fc fusion protein). Dr. Gillis received his B.A. from Williams College in 1975 and a PhD from Dartmouth College in 1978. He currently serves as a director or Chairman of multiple private and public biotechnology companies in the United States, Canada and New Zealand.